Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.3%

2 terminated out of 46 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

11%

5 trials in Phase 3/4

Results Transparency

25%

6 of 24 completed with results

Key Signals

6 with results92% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (20)
Early P 1 (1)
P 1 (6)
P 2 (7)
P 3 (3)
P 4 (2)

Trial Status

Completed24
Recruiting11
Active Not Recruiting6
Terminated2
Unknown2
Suspended1

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (46)

Showing 20 of 20 trials
NCT06126276Phase 2RecruitingPrimary

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

NCT05564377Phase 2Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT01552434Phase 1Active Not Recruiting

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

NCT07407647Phase 2Recruiting

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

NCT07215624Recruiting

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

NCT04475640Not ApplicableRecruiting

Cancer Genetic Testing in Ethnic Populations

NCT04266886Not ApplicableActive Not RecruitingPrimary

Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer

NCT03968406Phase 1RecruitingPrimary

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

NCT00791635Active Not Recruiting

Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer

NCT06525740Phase 4RecruitingPrimary

Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery

NCT06855524Phase 2Recruiting

Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer

NCT05786456Not ApplicableActive Not RecruitingPrimary

e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study

NCT06089083RecruitingPrimary

PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery

NCT05556772Not ApplicableActive Not RecruitingPrimary

Optimizing Screening for Cervical Cancer Among Women Living With HIV in the Dominican Republic

NCT04501913Completed

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes

NCT05625360Phase 3Recruiting

REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss

NCT06709534Not ApplicableRecruitingPrimary

An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors

NCT05105087Early Phase 1Completed

Gynecological Sentinel Lymph Nodes CEUS

NCT04596384Not ApplicableActive Not Recruiting

Home Base Telemonitoring in Gastrointestinal, Genitourinary, or Gynecologic Cancer Patients Undergoing Abdominal Surgery

NCT03037346Not ApplicableCompleted

Impact of a Systematic Social Work Driven Approach on Medical Power of Attorney Documentation, Knowledge, Attitudes, and Beliefs in Participants With Stage I-IV Gynecological Cancers

Scroll to load more

Research Network

Activity Timeline